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http://www.biomedcentral.com/1471-2474/15/256RESEARCH ARTICLE Open AccessPresence of the full-length KIR2DS4 gene reduces
the chance of rheumatoid arthritis patients to
respond to methotrexate treatment
Edyta Majorczyk1,2*, Andrzej Pawlik3, Daria Gendosz1 and Piotr Kuśnierczyk1*Abstract
Background: KIR genes coding for natural killer cell immunoglobulin-like receptors, KIR, influence the effector and
regulatory function of NK cells as well as some subpopulations of T lymphocytes (e.g. CD4+CD28-KIR+) depending
on presence of ligands (particularly HLA-C molecules). KIR-KIR ligand interaction may lead to the development of
autoimmune disorders, including rheumatoid arthritis (RA). However, their role in the response of RA patients to
methotrexate therapy is not known.
Methods: KIR genes and KIR-ligand (HLA-C C1/C2 allomorphs) genotyping was performed using the PCR-SSP
method in 312 RA patients (179 classified as good responders and 133 as poor responders using DAS28 criteria).
Thus, we evaluated the association of KIR genes and HLA-C allomorphs with the response to methotrexate (MTX)
treatment.
Results: We observed that patients possessing the full-length KIR2DS4 (KIR2DS4f) gene had a lower chance of
responding in comparison to KIR2DS4f-negative cases. This phenomenon was observed both in erosive disease (ED)
and rheumatoid factor (RF) positive and in ED- and RF-negative patients. Interestingly, the observed effect of the
KIR2DS4f gene was strongest in individuals possessing medium values (20-33 mm/h) of the erythrocyte sedimentation
rate (ESR). Patients with high ESR values had low probability and, in contrast, patients with low ESR had a high
probability of MTX response, and the presence of KIR2DS4f did not affect their outcome. Additionally, we show
that the KIR2DS4f effect did not depend on the presence of either C1 or C2 allomorphs.
Conclusion: Our results suggest that the response of RA patients with medium ESR values to MTX treatment may
be dependent on the full-length KIR2DS4 gene.
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Rheumatoid arthritis (RA) is a chronic, relatively prevalent
(about 1% of individuals in Caucasians) inflammatory dis-
order with a T cell-mediated autoimmune component [1].
Natural killer (NK) cells were also reported to contribute
to RA [2]. These cells may act both directly, killing target
cells, and indirectly, as either inducer or regulatory cells* Correspondence: e.majorczyk@po.opole.pl; pkusnier@iitd.pan.wroc.pl
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reproduction in any medium, provided the orinfluencing innate and adaptive immunity (a “two-edged
weapon”) [3].
The most polymorphic receptors of NK cells are en-
coded by killer cell immunoglobulin-like receptor (KIR)
genes distributed differently in unrelated individuals. Since
these receptors, depending on their structure, are either
inhibitory or activating, their repertoire in a genotype af-
fects activity of NK cells (and T cell subpopulations which
also express KIRs, including T lymphocyte CD4 + CD28-
KIR+) and, in consequence, susceptibility to different dis-
eases including autoimmune disorders such as RA [4-6].
KIR haplotypes (i.e., sets of KIR genes on one chromosome)
have been divided into group A, containing mostly inhibi-
tory genes, and group B, containing several activating genesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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gion was divided into centromeric (A or B) and telomeric
(A or B) halves, depending on the KIR gene content [7].
Ligands of KIRs, in most cases where known, are hu-
man leukocyte antigen (HLA) class I molecules which
are extremely polymorphic. KIR and HLA genes are lo-
cated on different chromosomes (number 19 and 6, re-
spectively); therefore they are independently inherited
and an individual may have KIRs with no ligands and
vice versa. This affects the maturation of NK cells and
the susceptibility of an individual to disease [8,9]. The
most important ligands of KIRs are HLA-C molecules,
which all fall into two groups: C1, with an asparagine
residue in position 80, and C2, with a lysine residue in
this position. KIR2DL1 and KIR2DS1 are receptors for
the C2 epitope, whereas KIR2DL2 and KIR2DL3 bind
C1 and also some C2 molecules. KIR2DS4 recognizes
HLA-A*11 molecules as well as some C1 and C2.
KIR2DL4 binds the “non-classical” class I molecule
HLA-G. KIR3DL1 and possibly KIR3DS1 bind HLA-B
with Bw4 epitope and those HLA-A alleles that possess
the Bw4 motif. KIR3DL2 binds HLA-A*03,*11, and mi-
crobial CpG DNA [10]. In addition, both KIR3DL1 and
KIR3DL2 bind HLA-B*27 homodimers [11,12].
As KIR and KIR ligand genotypes affect the immune re-
sponse, and seem to influence the response to RA treat-
ment using anti-TNF-α agents [13], we wondered whether
these genotypes might also influence the outcome of
MTX therapy of RA. MTX as a foliate antagonist is used
in therapy of malignant disorders, but also suppresses the
immune response in patients and in low doses was intro-
duced for the treatment of RA because of its presumed anti-
proliferative, immunosuppressive and anti-inflammatory
properties [14]. However, MTX is not sufficient in all RA
patients, and approximately 50-60% of RA patients could
be classified as MTX responders [15-18]. It seems that the
effectiveness of MTX treatment corresponds to the indi-
vidual genetic background, particularly in genes encoding
key molecules of methotrexate metabolism and toxicity
[19,20]. However, clinically reliable markers of methotrex-
ate efficiency are still sought.
Methods
Study subjects
Three hundred and twelve patients (253 females, 59
males; mean age, 58.0 ± 12.7 years, range 23-90; diseaseTable 1 Characteristics of patients with rheumatoid arthritis
Groups Number of cases Age
(females/males) (mean ± SD, r
All cases 312 (253/59) 58.0 ± 12.7, 2
Good responders 179 (143/36) 59.4 ± 12.4, 2
Poor responders 133 (110/23) 56.1 ± 12.9, 2duration, 10.0 ± 8.8 years, range 1-50; age at onset 48.0 ±
13.1, range 10-80) were diagnosed with RA according to
the criteria of the American College of Rheumatology
(Table 1). Patients were recruited from the outpatient and
inpatient population of the Department of Rheumatology,
County Hospital in Szczecin, Poland. All subjects were
Caucasian, from the Pomeranian region of Poland. The
subjects enrolled in the study underwent routine bio-
chemical blood analysis, and when required, assays for
anti-cardiolipin antibodies, anti-nuclear antibodies, and
immunological complexes. X-rays of the chest, hands, and
feet were obtained in all patients and, when required, ra-
diographs of other joints. These were interpreted by two
expert radiologists. The evaluation of the subjects included
physical examination, with particular focus on the pattern
of joint involvement and the occurrence of extra-articular
features (such as vasculitis, anemia, sicca syndrome, amyl-
oidosis, organ involvement) and laboratory features, such
as rheumatoid factor (RF) and anti-cyclic citrullinated pep-
tide antibodies (anti-CCP) screened for using appropriate
ELISA kits. Amyloidosis was diagnosed by histomorphol-
ogy (skin and bowel or duodenum biopsy), vasculitis by
histomorphology (skin biopsy) and angiogram.
All patients included in this analysis had a standard
methotrexate treatment with a regimen of oral 7.5 mg
weekly, and with the dosage increasing to 20 mg weekly
after 4 weeks, in combination with folic acid (1 mg
daily). No patients received any other disease-modifying
antirheumatic drug (DMARD), and no researchers’ in-
volvement in the patient care was practiced. A good
MTX response was noted for patients who were receiv-
ing MTX and had a disease activity score based on 28
joint counts (DAS28) of ≤2.5 at 6 months. Poor re-
sponders were defined as patients who were also receiv-
ing MTX but had a DAS28 of >2.5 [21,22].
The study was approved by the Committee of Ethical Af-
fairs of the Pomeranian Medical University in Szczecin and
written informed consent was obtained from all subjects.
DNA isolation, KIR and KIR ligand typing
These procedures were performed as described previ-
ously [23,24].
Statistical analysis
To investigate relationship between genetic, clinical
and anthropological variables and probability of aDisease duration Age at onset
ange) (mean ± SD, range) (mean ± SD, range)
3-90 10.0 ± 8.8, 1-50 48.0 ± 13.1, 10-80
3-84 9.0. ± 7.3, 1-37 50.4 ± 12.3, 19-77
4-90 11.3 ± 10.0, 1-50 44.9 ± 13.5, 10-80
Table 3 Full-length KIR2DS4 interaction in MTX response
dependent on bone erosion and rheumatoid factor
presence
MTX responsiveness Frequency (good responders/all)
ED RF 2DS4f presence 2DS4f absence
+ + 36.2 (21/58) 43.6 (48/110)
+ - 70.0 (14/20) 76.7 (33/43)
- + 72.7 (8/11) 72.4 (21/29)
- - 75.0 (12/16) 88.0 (22/25)
+, clinical factor detected; -, clinical factor absent.




2DS2 2DL3 2DL2 2DS3 2DL1 3DL1 3DS1 2DS5 2DS1 2DS4f* 2DS4d
Good responders (N = 179)
Presence (N) 107 155 103 68 178 171 59 52 71 55 156
Absence (N) 7 24 76 111 21 8 120 127 108 124 23
Frequency [%] 59.78 86.59 57.54 37.99 99.44 95.53 32.96 29.05 39.66 30.73 87.15
Poor responders (N = 133)
Presence (N) 75 121 71 33 129 121 46 41 55 50 110
Absence (N) 5 12 62 100 84 12 87 92 78 83 23
Frequency [%] 56.39 90.98 53.38 24.81 96.99 90.98 34.59 30.83 41.35 37.59 82.71
*Good responders vs poor responders: p = 0.0334; OR = 0.43, 95%CI = 0.215-0.987.
Majorczyk et al. BMC Musculoskeletal Disorders 2014, 15:256 Page 3 of 6
http://www.biomedcentral.com/1471-2474/15/256good response to MTX treatment, a generalized linear
model with binomial errors was used. The Akaike in-
formation criterion was used as a measure of fit of
models.
A bootstrap approach was employed to estimate model
coefficients and 95% confidence intervals. Odds ratio
(OR) was computed as a measure of effect size. Arith-
metic mean and standard deviation were calculated for
continuous variables. Haplotype frequencies for KIR rep-
ertoire were estimated with maximum likelihood func-
tion [25]. The likelihood ratio statistic, LRS, was used to
test the differences in haplotype frequencies between good
responders and poor responders. LRSdf = 21 = 2(LLgood +
LLpoor ‐ LLcombined) and LRS is approximately a χ
2
df = 21. Re-
sults were regarded as statistically significant at p < 0.05.
Results
A clinical response to MTX therapy was obtained for
57.3% of RA patients. When the frequencies of the KIR
genes were compared between good responders and
poor responders of RA patient groups, we observed an
effect of only one KIR gene, full-length KIR2DS4
(KIR2DS4f ), on the response to MTX therapy. Namely,
patients possessing this gene had a lower chance of
responding (p = 0.0334, OR = 0.4344, 95% CI = 0.215,
0.987; Table 2). Additionally, patients with erosive disease
(ED) and rheumatoid factor (RF) were less likely to re-
spond to MTX, and those positive for KIR2DS4f had an
even lower chance than those who were negative for
KIR2DS4f but positive for both ED and RF (36.2% and
43.6% of good responders, respectively; Table 3). Similarly,
RA patients negative for ED and RF also had a lower
chance of responding to MTX therapy if they possessed
KIR2DS4f (75% responding in comparison to 88% within
KIR2DS4f-negative patients; Table 3). On the other hand,
the presence of KIR2DS4f did not affect the formation of
RF (p = 0.89), ED (p = 0.78), or other clinical parameters
(data not shown).The KIR2DS4f gene is located in the telomeric half of
the KIR locus [7]. However, we did not observe any dif-
ferences between good and poor MTX responders in the
estimated haplotype frequencies for the telomeric KIR
repertoire (p = 0.29; Figure 1) despite the association of
the KIR2DS4f gene with a poor response to MTX de-
scribed above. Also, there were no differences in fre-
quencies of centromeric (p = 0.71) or whole KIR locus
(p = 0.96) genotypes between good and poor responders.
The effect of the KIR2DS4f gene on the probability of
a response to MTX in RF- and ED-positive patients was
strongest in individuals with medium values of the
erythrocyte sedimentation rate (ESR), that is, log(ESR)
about 3.0-3.5, i.e. 20-33 mm/h (Figure 2). Patients with
high ESR values had a low probability of responding,
and the presence or absence of KIR2DS4f did not affect
their outcome, particularly in individuals with low age at
onset. Patients with low ESR had a high probability of
responding, which was not affected by the presence of
KIR2DS4f, particularly in people with high age at onset
(Figure 2). The KIR2DS4f effect did not depend on the
presence of C1 (p = 0.209) or C2 (p = 0.484). Surpris-
ingly, the age at diagnosis had a negligible influence on
the KIR2DS4f effect.
Telomeric KIR genes Haplotype frequency








8 0.94 < 0.02
9 0.92 < 0.02
10 0.86 1.1
11 0.82 < 0.02
12 0.8 < 0.02
13 0.61 1.15
14 0.4 1.66




19 0.03 < 0.02
20 < 0.02 0.71
21 < 0.02 0.33
Σ 100% Σ 100%
Figure 1 Telomeric KIR haplotype profiles in MTX good responder and poor responder RA patient groups. Grey box: gene presence;
white box: gene absence. Estimation of KIR gene frequency based on haplotype distributions shown for KIR3DL1 – 81.5% and 78.7%, for KIR3DS1
18.6% and 21.5%, for KIR2DS5 15.9% and 18.1%, for KIR2DS1 22.4% and 26.0%, for KIR2DS4f 16.4% and 20.3%, for KIR2DS4d 63.3% and 56.3%, in
good responder and poor responder groups, respectively.
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This report confirms that almost one third of patients
affected by rheumatoid arthritis do not respond to low-
dose MTX treatment [15-18]. This phenomenon causes
that the discovery of (bio)markers of response to the
drug is still required for clinical practice. Here, we found
a negative association of the KIR2DS4f gene with the re-
sponse of RA patients to MTX treatment. This effect
was visible not only in RF-positive, ED-positive patients
who already had a lower chance of responding than nega-
tive ones, but also in RF- and ED-negative individuals who
otherwise were better responders. Therefore, it is likely
that the KIR2DS4f gene is expressed on effectors or posi-
tive regulators or inducers of autoimmune response,
relatively resistant to the MTX effect. In this context, the
CD4+CD28- subpopulation of T lymphocytes should be
discussed. This T cell subset is rare in healthy individuals(about 1% of peripheral lymphocytes), but its expansion
was observed in patients affected by, e.g., coronary artery
disease [26], polycystic ovary syndrome [27], multiple
sclerosis [28] and rheumatoid arthritis [4,29,30]. In
contrast to those isolated from healthy volunteers [31],
CD4+CD28- T cells from rheumatoid arthritis patients
may exhibit autoreactive properties [4]. Instead of the
CD28 molecule, these T cells frequently express activating
KIR receptors, as was shown by Yen et al. [32] particularly
for KIR2DS2 in RA vasculitis. Interestingly, it was sug-
gested that the KIR2DS4 gene may also be expressed on
CD4+CD28- T lymphocytes [33], and could transmit an
activating signal to effector cells. Therefore, KIR2DS4f
gene-positive patients might have a potential to produce
CD4+CD28-KIR2DS4+ T cells contributing to more se-
vere forms of RA, which would be more resistant to ther-
apy, including MTX treatment.
Figure 2 Probability difference in MTX response between KIR2DS4f-positive and KIR2DS4f-negative patients with similar RA baseline.
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polyspecific receptor recognizing both HLA-A*11 and
some HLA-C allotypes bearing C1 or C2 epitopes [10].
In Caucasians, including Poles, its gene is present in
roughly one third of KIR2DS4-positive individuals, the
other two thirds bearing its defective alleles, KIR2DS4d
(see www.allelefrequencies.net database) [34], potentially
encoding a soluble molecule which does not exhibit any
activating properties [35]. However, in Far East Orien-
tals, Japanese and Chinese, the proportions between
KIR2DS4f and KIR2DS4d are reversed [33]. It would be
interesting, then, to perform a similar analysis of RA pa-
tients’ response to MTX therapy in those populations,
especially as the KIR2DS4 gene seems to impact on RA
susceptibility in Taiwanese patients [36].
Some studies suggest that ESR level, mentioned as a bio-
marker for chronic systemic inflammation as well as a par-
ameter of disease activity, correlated with responsiveness
to MTX (reviewed by Romao et al.) [37]. In the present
study, we see that the effect of KIR2DS4f is strongest in in-
dividuals with medium susceptibility to the therapeutic ef-
fect of MTX characterized by an intermediate level of
ESR. Patients with high ESR are resistant to therapy, and
lack of the KIR2DS4f gene cannot help them; those with
low ESR respond so well that even the presence of the
KIR2DS4f gene does not cause any harm.
Conclusion
This study shows that the presence of the full-length
KIR2DS4 gene reduces the probability that patients af-
fected by rheumatoid arthritis will respond to methotrexate
therapy. This phenomenon was strongest in individuals
with a medium level (20-33 mm/h) of the erythrocytesedimentation rate. The patient cohort with lower values
of ERS responded better to MTX, while patients with a
higher ESR level responded worse to therapy, and the
presence of KIR2DS4f did not affect their outcome. There-
fore, our findings, if confirmed using an independent and
larger group of patients, might suggest that KIR typing
could help to predict the response to MTX therapy, espe-
cially for patients with moderate rheumatoid arthritis.
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